• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Clinical trial begins for non-invasive brain scanner to monitor intracranial hemorrhage

Bioengineer by Bioengineer
March 16, 2021
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

SENSE device uses low-power tailored radio frequency (RF) pulse to detect changes that may indicate expanding brain bleed; * Current standard of care lacks a means to monitor brain injury continuously, non-invasively, in real time, between CT scans

IMAGE

Credit: Sense Neuro Diagnostics

Sense Diagnostics announces initiation of clinical trial to evaluate a non-invasive brain scanner to monitor intracranial hemorrhage

  • SENSE device uses low-power tailored radio frequency (RF) pulse to detect changes that may indicate expanding brain bleed
  • Current standard of care lacks a means to monitor brain injury continuously, non-invasively, in real time, between CT scans

CINCINNATI, OH – March 16, 2021 – Sense Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, announced the initiation of a multicenter pivotal trial to evaluate the safety and efficacy of a non-invasive brain scanner to monitor intracranial hemorrhage (ICH) in an acute hospital setting. The SENSE device is a headset equipped with antennae that transmit a low-power tailored radio frequency (RF) pulse across the brain and uses an algorithm to detect signal changes that may indicate an expansion in ICH.

The trial, titled “A Prospective, Two-Stage, Non-randomized, Multi-center Within Patient Comparison Study to Evaluate the SENSE Device’s Ability to Monitor Intracranial Hemorrhage,” follows positive in vitro and in vivo proof of concept studies and a successful first in human feasibility study. The trial will enroll up to 400 patients with a diagnostic head CT scan demonstrating primary spontaneous ICH or traumatic ICH within 24 hours of symptom onset or injury. Patients may be actively monitored with the device for up to 48 hours, with results compared with data from regularly scheduled CT scans.

Each year nearly 800,000 people suffer strokes in the United States and 1.7 million Americans suffer traumatic brain injury. Ongoing or repeat bleeding in the brain, experienced by about 40% of patients following a hemorrhagic stroke and 50% of TBI patients, contributes to decreased brain function and poor outcomes. Repeat bleeding may be difficult to detect under the current standard of care, which is for a nurse or physician to assess the patient every one to eight hours by having the patient respond to a series of questions and commands.

“This rigorously designed trial marks important progress in our effort to assist patients and medical personnel by developing technology to monitor intracranial hemorrhage between CT scans and detect changes that may signal expansion of the bleed at the earliest opportunity,” said Opeolu Adeoye, MD, MS, Chief Medical Officer of Sense Diagnostics and Medical Director of the clinical trial.

The primary efficacy objective is to assess the positive predictive value of the SENSE device for detecting expansion of up to 3 ml for spontaneous ICH, or up to 6 ml for traumatic ICH, using the change in the CT scan as a reference standard. The study is being conducted to obtain approval of the device by the U.S. Food and Drug Administration.

###

About Sense Diagnostics

Sense Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes–ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage.

Learn more at https://senseneuro.com.

Media Contact:

Peg Rusconi

Communications Specialist

[email protected]

+1 617.910.6217

Media Contact
Peg Rusconi
[email protected]

Tags: Biomedical/Environmental/Chemical EngineeringClinical TrialsCritical Care/Emergency MedicineDiagnosticsHealth CareMedicine/HealthneurobiologyStrokeTrauma/Injury
Share12Tweet8Share2ShareShareShare2

Related Posts

GABA Best Detects Early Parkinson’s Changes with RBD

GABA Best Detects Early Parkinson’s Changes with RBD

August 6, 2025
Flavor and Bioactive Potential of Roasted Rice Bran Oil

Flavor and Bioactive Potential of Roasted Rice Bran Oil

August 5, 2025

New Research from Pitt Reveals Potential of Cellphone Data in Diagnosing and Treating Mental Health Disorders

August 5, 2025

New Scale Uncovers Why People Use Benzodiazepines

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    73 shares
    Share 29 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

GABA Best Detects Early Parkinson’s Changes with RBD

Flavor and Bioactive Potential of Roasted Rice Bran Oil

New Research from Pitt Reveals Potential of Cellphone Data in Diagnosing and Treating Mental Health Disorders

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.